Pomerantz Law Firm Probes EyePoint, Inc. for Investor Claims Amidst SEC Concerns

Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.

In a recent development within the financial sector, Pomerantz LLP has initiated an investigation on behalf of investors of EyePoint, Inc. (NASDAQ: EYPT), focusing on claims of potential securities fraud and unethical business practices related to significant recent announcements from the company. The firm encourages affected investors to reach out to Danielle Peyton via email or phone to discuss their legal options.

On August 17, 2026, EyePoint disclosed significant findings from their pivotal Phase 3 clinical trial regarding DURAVYU™ (vorolanib intravitreal insert), aimed at treating wet age-related macular degeneration (wet AMD). The release revealed that the trial did not meet its primary endpoint of demonstrating improvement in patients' visual acuity when compared to Regeneron Pharmaceuticals' Eylea. This news triggered a dramatic decline in EyePoint's stock price, which plummeted by nearly 67%, closing at $4.87 per share that day.

As if this wasn't enough, on October 19, 2026, EyePoint faced another setback when results from their second pivotal trial, LUCIA, were released, showing similarly disappointing outcomes. The company reported that DURAVYU failed to achieve the prespecified primary efficacy endpoint in assessing its effectiveness compared to Eylea. The resulting aftermath saw EyePoint's stock plummet once again, this time by over 85%, dropping to an alarming $0.44 per share by the end of the trading session.

Adding to these alarming revelations, EyePoint announced drastic measures, including a significant cut in operational costs alongside a 53% reduction in its workforce. These measures were intended to refocus the company on its ongoing diabetic macular edema programs, leaving investors in shock about the viability of their investments in the company.

Pomerantz LLP, known for its expertise in corporate and securities class litigation, has been a prominent voice for investors impacted by corporate misconduct. Founded over 85 years ago by Abraham L. Pomerantz, a recognized figure in the field of class actions, the firm has recovered substantial damages for class members in previous cases.

As Pomerantz continues to fight for the rights of investors, the urgency for EyePoint shareholders to explore their legal options becomes increasingly pronounced. Current and former investors are urged to examine their involvement with EyePoint and communicate any concerns to Pomerantz LLP.

This investigation highlights the persistent risks of investment in volatile sectors such as biotechnology and pharmaceuticals, where clinical trial results can majorly influence company valuations. EyePoint's recent failures serve as a reminder for investors to remain cautious and fully informed regarding the performance and practices of their investments.

For any investors seeking assistance or additional information regarding their rights, they can contact Pomerantz’s Danielle Peyton at the provided contact number or email. The financial repercussions of EyePoint’s recent trials and corporate strategies could reverberate throughout the biotechnology sector, raising broader concerns for investment stability in the field. Stay tuned for future updates as this story develops.